NEW YORK (GenomeWeb News) – Horizon Discovery today announced a £6.9 million ($10.5 million) final closing to its Series C funding round, bringing the total raised in the round to £18.2 million.

The closing of the round, the Cambridge, UK-based life science research tools firm said, will enable it to transition from a three-year investment phase to an organic growth phase "that it forecasts will deliver sustainable profit" from the second half of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.